Gilead Adds Inflammation Targets To Its 2020 R&D Collaboration With Arcus
Deal Snapshot: Already partnered on an anti-TIGIT drug and other immuno-oncology candidates, the firms will team up further on four targets in inflammatory disease.
You may also be interested in...
Deal Watch: Novartis Acquires Gene Therapy Candidate From AvroBio
AvroBio retains rights to its other HSC gene therapy candidates. Alimera Acquires Further Commercial Rights To Eyepoint’s Uveitis Drug.
Arcus And Gilead Keep TIGIT Dream Alive Despite Trial Shortcomings
Arcus and Gilead’s latest Phase II readout has produced mixed signals, but some analysts are reassured about the potential of domvanalimab and the wider TIGIT field.
Gilead Opts In On Multiple Arcus IO Candidates, Setting Up Combo Therapy Plans
Gilead is licensing two anti-TIGIT candidates and a pair of adenosine pathway-targeted drugs. The firms will study various IO combo regimens, possibly including Gilead drugs like Trodelvy.